The oral Pharmaceutical combination is useful to restore alterations of intestinal function and comprises a therapeutically effective amount of an active Principle for the treatment of different gastrointestinal Functional Disorders and a probiotic with Pharmaceutical Excipients u00e9uticamente acceptable.Can understand the principle propinox cinitapride, Trimebutine, esomeprazole, lansoprazole, dexlansoprazole, ranitidine, famotidine, cimetidine or propinox combined with lysine clonixinate.The probiotic bacterial Strain can be selected among a bifido bacteria Lactobacillus sp, SP, Bacillus sp, SP lactococcal, Streptococci, Enterococci and yeasts such as bifido bacterium Brief or brevis bifido bacterium, Bifidobacterium lactis, Bifidobacterium longum, animalis, LACT Obacillus acidophilus Lactobacillus reuteri, Lactobacillus casei, Lactobacillus bulgaricus,Lactobacillus plantarum Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus salivarius, Lactobacillus fermentum, Lactobacillus johnsonii, Lactobacillus helveticus, Lactobacillus delbrueckii, Bacillus subtilis, Bacillus clausii, Streptococcus thermophilus, Streptococcus faecium, streptoco CCUs fecalis Enterococcus faecalis, Bacillus coagulans,Propionibacterium freudenreichii and sacaromyces boulardi, in an interval between x 1 and x 10 u00b9 u2074 10 u00b3 UFC 1 CFU per dosage Unit. The pharmaceutical Combination can include a therapeutically effective amount of a selected nutraceutic between a prebiotic, or a Vitamin A min Eral.La combinación farmacéutica oral es útil para restablecer alteraciones de la función intestinal y comprende cantidades terapéuticamente efectivas de un principio activo para el tratamiento de los distintos trastornos funcionales gastrointestinales y de un probiótico junto a excipientes farmacéuticamente aceptables. El principio puede comprender trimebutina, cinitaprida, propinox, lansoprazol, esomeprazol, dexlansoprazol, ranitidina, famotidina, cimetidina o propinox combinado co
